Here are five observations:
1. The company’s proposed tax-free spin-off of QiG Group will be called Nuvectra after the process is complete.
2. Nuvectra will be a neuromodulation medical device company initially focused on the development and commercialization of a neurostimulation technology platform.
3. Joseph A. Miller, Jr., PhD, has been named director and chairman of the board of Nuvectra. He served on Greatbatch’s board of directors but will step to take up his new role with Nuvectra.
4. Scott Drees has been named as Nuvectra’s CEO. He previously served as neuromodulation portfolio manager for QiG Group.
5. The spin-off is expected to be completed by the end of 2015. However, it is subject to a number of considerations including final approval of Greatbatch’s board of directors.
More articles on devices:
Medovex signs distribution agreement with Aureus Medical: 5 key facts
Blue Belt Technologies partners with Acibadem Healthcare Group for orthopedic surgical robotics center: 5 key points
LifeScience Alley appoints Sheri Dodd of Medtronic to board of directors: 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
